Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study-Reference-Cited by-同舟云学术

Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study

Author:

Balsa Alejandro¹,Sanmarti Raimon²,Rosas José³,Martin Victor⁴,Cabez Ana⁵,Gómez Susana⁶,Montoro María⁶

Affiliation:

1. Department of Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain

2. Arthritis Unit, Department of Rheumatology, Hospital Clinic de Barcelona and IDIBAPS, Barcelona, Spain

3. Department of Rheumatology, Hospital Marina Baixa, Villajoyosa, Alicante, Spain

4. Biostatistics, Pfizer España, Madrid, Spain

5. Medical Affairs, Pfizer España, Madrid, Spain

6. Inflammation Rheumatology, Medical Department, Pfizer SLU, Madrid, Spain

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

Reference20 articles.

1. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheum,2016

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Towards Personalized Medicine in Rheumatoid Arthritis;Open Access Rheumatology: Research and Reviews;2024-05